Last reviewed · How we verify
NCT04713501: PARTS1
Program for Alleviating and Resolving Trauma and Stress 1
NA trial testing PARTS Program in Post-traumatic Stress Disorder in 15 participants. Completed in 31 July 2021.
31 July 2021
Quick facts
| Lead sponsor | Cambridge Health Alliance |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 22 December 2020 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PARTS Program
Conditions studied
- Post-traumatic Stress Disorder — all drugs for Post-traumatic Stress Disorder →
Sponsor
Cambridge Health Alliance — full company profile →
Who can join
Adults 18 to 70, any sex, with Post-traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-arm pilot study (Phase 1) will test the preliminary efficacy of a virtually delivered, live-online 16-week group model of Internal Family Systems (IFS) for individuals with PTSD, called the PARTS program, on PTSD symptoms measured by Clinician-Administered PTSD Scale (CAPS-5). In addition, feasibility, acceptability, and effects on self-report PTSD and disturbances of self-organization (DSO) will be secondary outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04713501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PARTS Program
Trials testing the same drug.
- NCT05095428 — Program for Alleviating and Resolving Trauma and Stress 2 · NA · completed
Other recruiting trials for Post-traumatic Stress Disorder
Currently open trials in the same condition.
- NCT06943404 — BXCL501 After Stress to Increase Recovery Success · Phase 2 · recruiting
- NCT06477796 — Improving Sleep in Veterans With the Polytrauma Clinical Triad · NA · recruiting
- NCT06538246 — Adaptive Coping Skills Training to Improve Psychological Distress Among Cardiorespiratory Failure Survivors · NA · recruiting
- NCT06592677 — Early Support After Exposure to Trauma · NA · recruiting
- NCT05927324 — Clinician-Assisted Videofeedback Exposure-Approach Therapy (CAVEAT) Trial · NA · recruiting
Other Cambridge Health Alliance trials
Trials by the same sponsor.
- NCT06419595 — Screening and Support for Youth (SASY) · NA · not yet recruiting
- NCT07513220 — The Effectiveness and Acceptability of Formal Versus Informal Mindful Self-Compassion for Adolescents · NA · not yet recruiting
- NCT06988462 — Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food · NA · recruiting
- NCT06564948 — Treatment for Individuals Interacting with the Criminal Justice System · NA · recruiting
- NCT06765122 — Program for Alleviating and Reducing Trauma and Stress for Intimate Partner Violence · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04713501 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge Health Alliance
- Last refreshed: 12 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04713501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing